Analysts have set 12-month price targets for Neurocrine Biosciences, revealing an average target of $155.06, a high estimate of $182.00, and a low estimate of $115.00. This current average reflects an ...

Analysts have given Moderna a total of 6 ratings, with the consensus rating being Neutral. The average one-year price target ...

Neurocrine Biosciences continues strong with Ingrezza and Crenessity growth, plus a promising pipeline in MDD and ...

Neurocrine Biosciences Inc (NBIX) reports robust sales growth in Q2 2025, driven by strong performance of INGREZZA and CRENESSITY, while navigating pricing challenges and strategic investments.

Discover key insights from Neurocrine Biosciences' Q2 2025 earnings, featuring record INGREZZA growth, CRENESSITY's rapid adoption, and strategic ...

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best strong buy healthcare stocks to buy now. On July 22, Morgan ...

Atai Life Sciences and its partner Recognify Life Sciences said on Friday their experimental drug did not meet the main goal in a mid-stage trial for patients with schizophrenia-linked cognitive ...

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Neurocrine Biosciences (NasdaqGS:NBIX) with a ...

SAN FRANCISCO -- Crinecerfont (Crenessity) may help improve metabolic profiles of adults and children with classic congenital adrenal hyperplasia (CAH), analyses of phase III CAHtalyst trial data ...